Myriad, Janssen R&D Using BRACAnalysis in Phase III Study for Yondelis | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics and Janssen Research & Development today announced they will use Myriad's BRACAnalysis test in a Phase III clinical trial for Yondelis (trabectedin).

Janssen is developing Yondelis as a treatment for advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancers. The firm is studying the drug in combination with a chemo regimen in the third-line setting comparing it against just chemotherapy in patients who have had two previous lines of platinum-based chemo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.